See more : Level Biotechnology Inc. (3118.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of PepGen Inc. (PEPG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PepGen Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fisco Ltd. (3807.T) Income Statement Analysis – Financial Results
- Taiwan Numerical Powers Co., Ltd. (6593.TWO) Income Statement Analysis – Financial Results
- Macau Property Opportunities Fund Limited (MPO.L) Income Statement Analysis – Financial Results
- Sparta Capital Ltd. (SCAXF) Income Statement Analysis – Financial Results
- Bellevue Gold Limited (BGL.AX) Income Statement Analysis – Financial Results
PepGen Inc. (PEPG)
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.18M | 493.00K | 178.00K | 110.00K | 106.00K |
| Gross Profit | -1.18M | -493.00K | -178.00K | -110.00K | -106.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 66.94M | 54.08M | 19.00M | 1.02M | 620.00K |
| General & Administrative | 16.64M | 14.22M | 8.11M | 853.00K | 628.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 627.37K |
| SG&A | 16.64M | 14.22M | 8.11M | 853.00K | 628.00K |
| Other Expenses | 0.00 | 110.00K | -172.00K | -20.00K | 0.00 |
| Operating Expenses | 84.77M | 68.30M | 27.11M | 1.88M | 1.25M |
| Cost & Expenses | 84.77M | 68.30M | 27.11M | 1.88M | 1.35M |
| Interest Income | 6.40M | 2.79M | 0.00 | 8.00K | 6.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.18M | 493.00K | 178.00K | 110.00K | 106.00K |
| EBITDA | -83.58M | -67.81M | -26.93M | -1.77M | -1.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -84.77M | -68.30M | -27.11M | -1.88M | -1.35M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.21M | 2.90M | -172.00K | -12.00K | 8.00K |
| Income Before Tax | -78.55M | -65.40M | -27.28M | -1.89M | -1.35M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 73.00K | 3.71M | -58.56K | -8.00K | 0.00 |
| Net Income | -78.63M | -69.10M | -27.28M | -1.88M | -1.35M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.30 | -2.91 | -1.22 | -0.08 | -0.06 |
| EPS Diluted | -3.30 | -2.91 | -1.22 | -0.08 | -0.06 |
| Weighted Avg Shares Out | 23.80M | 23.71M | 22.39M | 22.39M | 22.39M |
| Weighted Avg Shares Out (Dil) | 23.80M | 23.71M | 22.39M | 22.39M | 22.39M |
The Schall Law Firm Is Investigating Whether PepGen Inc. Violated Securities Laws And Affected Stockholders Should Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
Investors Are Invited To Join The Schall Law Firm's Inquiry Into PepGen Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
The Schall Law Firm Is Investigating Whether PepGen Inc. Violated Securities Laws And Stockholders With Losses Should Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
PepGen Inc Is Being Looked Into For Securities Related Infractions And Affected Investors Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
The Schall Law Firm Wants Shareholders To Join An Inquiry Into PepGen Inc. For Violating Securities Laws
LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
PepGen Inc Is Being Investigated By The Schall Law Firm For Securities Fraud And Impacted Investors Are Urged To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that Christopher Ashton, PhD, intends to retire from the...
The Schall Law Firm Encourages Shareholders With Losses In PepGen Inc To Take Part In An Inquiry For Securities Related Infractions
LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
PepGen Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
The Schall Law Firm Wants Shareholders With Losses In PepGen Inc To Assist With An Inquiry Into Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / September 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
Source: https://incomestatements.info
Category: Stock Reports